Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florence Lerebours

Showing results (31-40 of 100) with videos related to

Pageof 10
Sort By:
British Journal of Cancer|February 21, 2018
Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohortAnne-Sophie Hamy, Lisa Belin, Hélène Bonsang-Kitzis, et al.
British Journal of Cancer|December 15, 2015
Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohortAnne-Sophie Hamy, Lisa Belin, Hélène Bonsang-Kitzis, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 2, 2018
Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institutionJoy Bacrie, Marc Laurans, Pauline Iorio, et al.
Cancers|May 14, 2022
Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie HospitalsClelia Chalumeau, Matthieu Carton, Alexandre Eeckhoutte, et al.
Oncogene|October 19, 2002
Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancerElizabeth Turpin, Ivan Bièche, Philippe Bertheau, et al.
Molecular Cancer|March 1, 2011
Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidyIvan Bièche, Sophie Vacher, François Lallemand, et al.
Plos One|January 24, 2019
Impact of time to local recurrence on the occurrence of metastasis in breast cancer patients treated with neoadjuvant chemotherapy: A random forest survival approachEnora Laas, Anne-Sophie Hamy, Anne-Sophie Michel, et al.
JAMA Network Open|August 19, 2024
Cognition and Return to Work Status 2 Years After Breast Cancer DiagnosisMarie Lange, Justine Lequesne, Agnes Dumas, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 7, 2024
Pre-treatment [18F]FDG PET/CT biomarkers for the prediction of antibody-drug conjugates efficacy in metastatic breast cancerRomain-David Seban, Laurence Champion, Alexandre De Moura, et al.
Journal of Translational Medicine|April 18, 2024
Mutational landscape of inflammatory breast cancerFrançois Bertucci, Florence Lerebours, Michele Ceccarelli, et al.
Pageof 10

Showing results (31-40 of 100) with videos related to

Sort By:
Pageof 10
British Journal of Cancer|February 21, 2018
Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohortAnne-Sophie Hamy, Lisa Belin, Hélène Bonsang-Kitzis, et al.
British Journal of Cancer|December 15, 2015
Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohortAnne-Sophie Hamy, Lisa Belin, Hélène Bonsang-Kitzis, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 2, 2018
Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institutionJoy Bacrie, Marc Laurans, Pauline Iorio, et al.
Cancers|May 14, 2022
Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie HospitalsClelia Chalumeau, Matthieu Carton, Alexandre Eeckhoutte, et al.
Oncogene|October 19, 2002
Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancerElizabeth Turpin, Ivan Bièche, Philippe Bertheau, et al.
Molecular Cancer|March 1, 2011
Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidyIvan Bièche, Sophie Vacher, François Lallemand, et al.
Plos One|January 24, 2019
Impact of time to local recurrence on the occurrence of metastasis in breast cancer patients treated with neoadjuvant chemotherapy: A random forest survival approachEnora Laas, Anne-Sophie Hamy, Anne-Sophie Michel, et al.
JAMA Network Open|August 19, 2024
Cognition and Return to Work Status 2 Years After Breast Cancer DiagnosisMarie Lange, Justine Lequesne, Agnes Dumas, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 7, 2024
Pre-treatment [18F]FDG PET/CT biomarkers for the prediction of antibody-drug conjugates efficacy in metastatic breast cancerRomain-David Seban, Laurence Champion, Alexandre De Moura, et al.
Journal of Translational Medicine|April 18, 2024
Mutational landscape of inflammatory breast cancerFrançois Bertucci, Florence Lerebours, Michele Ceccarelli, et al.
Pageof 10